Introduction Dabrafenib is an oral targeted anticancer drug marketed under the brand name Tafinlar. Pharmacologically, dabrafenib is a BRAF kinase inhibitor used in selected cancers with activating BRAF mutations. The BRAF protein is a serine/threonine kinase in the RAS-RAF-MEK-ERK signaling pathway, also called the MAPK pathway. This pathway normally transmits growth signals from cell-surface receptors … Read more
Introduction Asciminib is an oral targeted anticancer drug marketed under the brand name Scemblix. Pharmacologically, asciminib is an ABL/BCR-ABL1 tyrosine kinase inhibitor used in Philadelphia chromosome-positive chronic myeloid leukemia, commonly abbreviated as Ph+ CML. Chronic myeloid leukemia is driven by the Philadelphia chromosome, which forms due to a translocation between chromosomes 9 and 22. This … Read more
Introduction Sotorasib is an oral targeted anticancer drug marketed under the brand name Lumakras. Pharmacologically, sotorasib is a KRAS G12C inhibitor and belongs to the class of RAS GTPase inhibitors. KRAS is an important intracellular signaling protein involved in cell growth, proliferation, differentiation, survival, and apoptosis regulation. Normally, KRAS works like a molecular switch. It … Read more
Introduction Amivantamab is a targeted anticancer monoclonal antibody used in selected patients with non-small cell lung cancer, commonly abbreviated as NSCLC. It is marketed under the brand name Rybrevant as intravenous amivantamab-vmjw. A subcutaneous formulation, Rybrevant Faspro, contains amivantamab with hyaluronidase-lpuj, but the key anticancer antibody component is amivantamab. Pharmacologically, amivantamab is a bispecific antibody … Read more
